765880-61-3

Usage

Uses

Used in Pharmaceutical Industry:
6-Chloro-chroman-4-ylamine is used as a key intermediate in the synthesis of potential drug candidates for various medical applications, including the development of new therapeutic agents.
Used in Anti-Inflammatory Applications:
6-Chloro-chroman-4-ylamine is utilized for its anti-inflammatory properties, which can be beneficial in the treatment of conditions characterized by inflammation.
Used in Antimicrobial Applications:
6-CHLORO-CHROMAN-4-YLAMINE is employed for its antimicrobial properties, making it a potential candidate for use in treatments targeting bacterial infections.
Used in Neurological Disorder Treatment:
6-Chloro-chroman-4-ylamine has been investigated for its potential role in the treatment of neurological disorders, suggesting its use as a therapeutic agent in this field.
Used in Cancer Treatment Research:
6-Chloro-chroman-4-ylamine is studied for its potential role in cancer treatment, indicating its use in research aimed at developing new oncology drugs.

InChI:InChI=1/C9H10ClNO/c10-6-1-2-9-7(5-6)8(11)3-4-12-9/h1-2,5,8H,3-4,11H2

Upstream product

• 37674-72-9 6-chloro-chroman-4-one 
• 147592-12-9 6-chloro-chroman-4-ol 
• 3284-79-5 3-(4-chlorophenoxy)propionic acid 
• 106-48-9 4-chloro-phenol 

Downstream Products

• 1394153-58-2 N-[6-chlorochroman-4-yl]-N'-(3-nitrophenyl)thiourea 
• 1394153-57-1 N-[6-chlorochroman-4-yl]-N'-(4-nitrophenyl)thiourea 

Relevant academic research and scientific papers

N-Aryl-N'-(chroman-4-yl)ureas and thioureas display in vitro anticancer activity and selectivity on apoptosis-resistant glioblastoma cells: Screening, synthesis of simplified derivatives, and structure-activity relationship analysis

A series of chroman derivatives previously reported as potassium channel openers, as well as some newly synthesized simplified structures, were examined for their in vitro effects on the growth of three human high-grade glioma cell lines: U373, T98G, and Hs683. Significant in vitro growth inhibitory activity was observed with 2,2-dimethylchroman-type nitro-substituted phenylthioureas, such as compounds 4o and 4p. Interestingly, most tested phenylureas were found to be slightly less active, but more cell selective (normal versus tumor glial cells, such as 3d, 3e, and 3g), thus less toxic, than the corresponding phenylthioureas. No significant differences were observed in terms of chroman-derivative-induced growth inhibitory effects between glioma cells sensitive to pro-apoptotic stimuli (Hs683 glioma cells) and glioma cells associated with various levels of resistance to pro-apoptotic stimuli (U373 and T98G glioma cells), a feature that suggests non-apoptotic-mediated growth inhibition. Flow cytometry analyses confirmed the absence of pro-apoptotic effects for phenylthioureas and phenylureas when analyzed in U373 glioma cells and demonstrated U373 cell cycle arrest in the G0/G1 phase. Computer-assisted phase-contrast videomicroscopy revealed that 3d and 3g displayed cytostatic effects, while 3e displayed cytotoxic ones. As a result, this work identified phenylurea-type 2,2-dimethylchromans as a new class of antitumor agents to be further explored for an innovative therapeutic approach for high-grade glioma and/or for a possible new mechanism of action.

2-Benzimidazolyl-9-(chroman-4-yl)-purinone derivatives as JAK3 inhibitors

A novel class of Janus tyrosine kinase 3 (JAK3) inhibitors based on a 2-benzimidazoylpurinone core structure is described. Through substitution of the benzimidazoyl moiety and optimization of the N-9 substituent of the purinone, compound 24 was identified incorporating a chroman-based functional group. Compound 24 shows excellent kinase activity, good oral bioavailability and demonstrates efficacy in an acute mechanistic mouse model through inhibition of interleukin-2 (IL-2) induced interferon-γ (INF-γ) production.

8-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE DERIVATIVES FOR IMMUNOSUPPRESSION

The present invention provides novel purines useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula I:

7-Substituted Purine Derivatives for Immunosuppression

The present invention provides novel purinone and related derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula III: